RxDoctor Payments Data

Heidi Biringer, PA

Physician Assistant · Wesley Chapel, FLNPI 1003832205

Payments from drug & device makers

$5,290in general payments, 2019–2025

Across 191 payments — averaging $27.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$1K
  • AbbVie$587
  • Johnson & Johnson$453
  • Abbott$358
  • Pfizer$342
  • Lilly USA, LLC$324
  • plus $2K from 28 others

What the payments were for

  • Food & beverage$5,19698%
  • Education$942%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,290 in reported general payments places this provider in the 90th percentile of 8,062 physician assistant providers in Florida.

See all physician assistant providers in Florida

Medicare billing

Part B allowed, 2024
$41,821
Medicare patients
130
Services billed
608

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide38$48,773
MounjaroTirzepatide22$22,504
JardianceEmpagliflozin15$19,177
LinzessLinaclotide12$7,920
Lantus SolostarInsulin Glargine,hum.Rec.Anlog12$3,997
Olmesartan-HydrochlorothiazideOlmesartan/Hydrochlorothiazide53$2,300
Atorvastatin Calcium182$2,210
SynthroidLevothyroxine Sodium23$1,889
Levothyroxine Sodium148$1,639
Rosuvastatin Calcium108$1,039
Olmesartan Medoxomil51$976
Amlodipine-ValsartanAmlodipine Besylate/Valsartan38$905
Potassium Chloride29$660
Duloxetine Hcl30$623
Escitalopram Oxalate54$596

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$1,032$48,77338 claims
Lilly USA, LLCMounjaro$324$22,50422 claims
Boehringer IngelheimJardiance$203$19,17715 claims
AbbVieLinzess, Synthroid$587$9,80935 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 8,062 physician assistant providers in Florida.

Other physician assistant in Wesley Chapel

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →